In the intent-to-treat population ( n = 410 ) , there was a prolongation by WBRT of both PFS ( 15.4 vs 9.9 months , HR 0.79 [ 95 % CI 0.64-0 .98 ] , p = 0.034 ) and PFS from last HDMTX ( 19.4 vs 11.9 months , HR 0.72 [ 95 % CI 0.58-0 .89 ] , p = 0.003 ) , but not of OS ( 32.4 vs 36.1 months , HR 0.98 [ 95 % CI 0.79-1 .26 ] , p = 0.98 ) .